Background: Both gemcitabine and docetaxel have been associated with pulmonary toxicity when used as single agents. We report a study in which three of five cases developed pulmonary toxicity (which proved fatal in one case) when these drugs were used in combination to treat metastatic transitional cell cancer.
Background
Metastatic transitional cell carcinoma (TCC) is a moderately chemosensitive disease which, during the last 15 years, has been predominantly treated by Oncologists with cisplatin-containing combination chemotherapy e.g., MVAC (methotrexate, vinblastine, doxorubicin and cisplatin) [1] . This treatment is, however, toxic and noncurative -with a five-year disease-free survival of only 3.7% reported in a recent randomised trial [2] .
A number of new drugs have shown highly promising activity in phase II studies of solid tumours. These include the taxanes (paclitaxel and docetaxel) and gemcitabine [3] [4] [5] [6] [7] [8] [9] [10] [11] [12] . Pulmonary toxicity has occasionally been reported with each of these drugs when used either as single agents or in combination with irradiation [13] [14] [15] [16] [17] [18] [19] [20] [21] . We report a phase I study of a combination of docetaxel and gemcitabine (DG) in patients with metastatic transitional cell carcinoma in which an unexpectedly high incidence of pulmonary toxicity has occurred, causing premature suspension of the study.
Patients and methods
Patients included in this study had histologically confirmed transitional cell carcinoma (TCC) of the bladder with metastatic and bidimensionally measurable disease. Eligible patients were aged 18-75 years with an ECOG performance status of 0-2. The study required that patients had adequate bone marrow function (peripheral white cell count >3.5 x 10 9 /l and platelet count > 150 x 10 9 /l) and renal function (glomerular filtration >60 ml/min). All patients had a normal bilirubin, with transaminase and alkaline phosphatase levels not greater than, respectively, 1.5 and 2.5x the upper limit of normal levels. Patients had a life expectancy of at least 12 weeks. The protocol was passed by the local ethics committee.
Five patients with metastatic TCC were treated with docetaxel and gemcitabine; none of these patients had received either previous chemotherapy or irradiation to the chest. All patients were treated on a 21-day cycle. Docetaxel was given intravenously on day 1 as a one hour infusion at a dose of 60 mg/m 2 . Oral dexamethasone. 8 mg 12 hourly, was commenced 24 hours prior to this treatment and continued for a total of 72 hours. Gemcitabine was given as a 30-minute intravenous infusion immediately after administration of the docetaxel at a dose of 1 G/m 2 . This drug was also given, as a single agent, in the same manner on day 15.
Patients were monitored during treatment with weekly full blood counts and biochemistry. After commencing chemotherapy dose modifications were made according to the following criteria: neutrophil count >1.5 x !0 in full dose if the neutrophil count was > 1.0 x 10 /I and platelet count > 100 x 10 9 /l. This dose was reduced to 75% if the neutrophils were 0.5-1 x 1O 9 /1 or platelets 50-100 x 1O 9 /1 and was omitted if counts were lower than this. Gemcitabine doses were also reduced if renal function was impaired -GFR > 50 ml/min -100% dose, 40-60 ml/min -50% dose, <40 ml/min -dose omitted. Docetaxel was omitted if the bilirubin was elevated above normal or if the ALT was greater than 1.5x normal levels and/or ALP levels greater than 2.5x normal. Gemcitabine was omitted if any other toxicity exceeded grade 3 WHO levels (except nausea, vomiting and alopecia).
Three patients developed significant pulmonary toxicity; for one of these patients this proved fatal.
Case 1
A 56-year-old man presented with a large right sided bladder tumour which was bimanually palpable after resection (T3). Histologically, after examination of transurethral tumour resection specimen, this proved to be a G3pT2+ transitional cell carcinoma. A CTscan showed the mass in the bladder with widespread pelvic and retroperitoneal lymph node enlargement.
Five days after receiving day 1 of cycle 2a of DG chemotherapy he attended with a four day history of exertional dyspnoea. He was pyrexial (38.5 °C) but the remainder of the physical examination was unremarkable. A full blood count and CXR were normal. Urinary cultures revealed an infection and he was treated with the appropriate antibiotics. Cycle 2b was administered despite persisting exertional dyspnoea and, the CXR remained normal. This course was complicated by neutropenic fever treated with azlocillin and gentamicin. He returned for his third course but was noted to still be suffering with (grade 2) exertional dyspnoea. His creatinine had risen (183 mmol/1) and he was clinically dehydrated. Intravenous fluids were given resulting in a rapid normalisation of his renal function.
His treatment was changed to CMV from which he gained a complete response. His dyspnoea rapidly and completely resolved following cessation of DG combination and commencement of CMV. He developed progressive disease but remains alive, 12 months since the start of treatment.
Case 2
A 66-year-old man presented with muscle invasive TCC of the bladder invading the ureter. He was treated with 60 Gy of radiotherapy to the pelvis. His disease recurred in the bladder two years later at which time he proceeded to cystectomy and ileal-conduit formation. A further two years later he developed a biopsy proven anorectal recurrence.
A defunctioning colostomy was performed and treatment with docetaxel and gemcitabine was commenced. Prior to his third course of treatment his CXR showed subtle peri-hilar ground glass shadowing. However he had no chest symptoms or signs. He received his third cycle of day 1 treatment uneventfully. Thirteen days later his blood count was normal but he complained of exertional dyspnoea; day 15 treatment was withheld because of grade 3 WHO pulmonary toxicity. He desaturated from 97% oxygen saturation on air at rest to 85% on minimum exertion. His resting arterial blood gas on air indicated hypoxia with a pO2 of 8.63. His CXR showed evidence of progressive pulmonary infiltrates ( Figure 1) .
A bronchoscopy and transbronchial biopsy were performed. Immediately following the procedure a small pneumothorax was found on CXR, this was aspirated but the patient developed increasing respiratory distress with hypoxia. The pneumothorax worsened requiring an intercostal drain to be inserted. He then received high dose inspired oxygen and was commenced on co-trimoxazole and hydrocortisone in case of pneumocystis infection. Despite these measures he continued to deteriorate becoming increasingly hypoxic whilst receiving 60% oxygen. The right lung would not fully inflate and the pulmonary infiltrates progressively worsened. He developed respiratory failure and died. His CXR showed changes consistent with adult respiratory distress syndrome. A transbronchial biopsy was performed and revealed type 2 pneumocyte hyperplasia together with patchy interstitial fibrosis and some fibrinous exudate within alveoli. A minimal inflammatory cell infiltrate, composed of lymphocytes, neutrophils and eosinophils, was present. Additional stains for acid-fast bacilli and fungi were negative. The appearances were those of diffuse alveolar damage/adult respiratory distress syndrome. Possible underlying causes for the changes included acute viral pneumonia, oxygen toxicity or chemotherapyinduced lung damage. The relative lack of inflammation would have been unusual for viral pneumonia and with the clinical history it was believed most likely that the changes had occurred secondary to the chemotherapy.
Post mortem examination revealed that both lungs were markedly increased in weight (left lung 812 g, right lung 842 g). There was no macroscopic evidence of tumour deposits within the lungs or remaining organs. Histological examination (Figure 2 ) revealed similar changes to those within the transbronchial biposy. Widespread type 2 pneumocyte hyperplasia was present together with hyaline membrane formation, areas of fibrous thickening of alveolar walls and organising exudate within alveoli. No significant inflammatory cell infiltrate was identified. The appearances were again interpreted as those of diffuse alveolar damage/adult respiratory syndrome, which was most likely to have occurred secondary to chemotherapy. Immunohistochemical staining for cytomegalovirus was negative and no viruses were cultured from the fresh lung tissue. Histology also revealed scattered islands of carcinoma cells within lymphatic spaces in the lung parenchyma and pleura consistent with metastatic transitional cell carcinoma.
Case 3
A 73-year-old man with known chronic obstructing airways disease presented with haematuria. Cystoscopy revealed a bladder tumour and cystectomy with formation of an ileal conduit was performed for what proved to be a G3pT 3a TCC.
One month post-operatively he developed haemoptysis and a chest X-ray confirmed the presence of pulmonary metastases. He commenced DG chemotherapy. At day 14 of his first cycle he complained of an increase in his shortness of breath. However his haemoptysis had resolved. A VQ scan showed a matched reduction in ventilation and perfusion in the upper lobe of both lungs consistent with chronic lung disease so he proceeded to cycle lb. After cycle 2 his shortness of breath had deteriorated further and was graded at WHO 3-4. He became pyrexial and an MSU revealed a urinary tract infection. A CXR showed left lower zone shadowing. A high resolution CTscan of the lungs showed widespread ground glass parenchymal shadowing together with some coarse reticular shadowing in the lower lobes ( Figure 3) . He was treated with antibiotics and hydrocortisone but was too unwell to tolerate a bronchoscopy. Cotrimoxazole was also commenced to cover pneumocystis infection. The pulmonary infiltrates gradually resolved and his dyspnoea recovered; DG was discontinued. Four weeks after this incident, at a time when his dyspnoea had largely resolved, he died of progressive malignant disease.
Post mortem examination revealed that the lungs were slightly but not markedly increased in weight (left lung 384 g, right lung 404 g). Both lungs contained multiple metastatic tumour deposits individually measuring up to 40mm across. Further metastases were identified within the liver and pancreas. Histological examination of the lungs confirmed the presence of metastatic carcinoma and revealed some emphysematous destruction of alveolar walls together with scattered foci of organising pneumonia. Occasional foci of fibrin deposition were present within alveoli but no established hyaline membranes were present. These changes were considered to be non-specific in nature and were of insufficient severity for a diagnosis of diffuse alveolar damage.
Discussion
Pulmonary toxicity has been recorded following administration of both the deoxycytidine analogues cytarabine and gemcitabine, and the taxanes, paclitaxel and docetaxel [13] [14] [15] [16] [17] [18] [19] [20] [21] [22] [23] . Most reports have described this toxicity as mild and self-limiting [13] . However more recently the literature has indicated that pulmonary problems can rarely be more severe and even fatal [13] .
In cytarabine treated patients pulmonary toxicity has occurred when used in intermediate and high dose to treat acute myeloid leukaemia [22, 25, 28] . As many as 28% of patients are said to be affected and the condition may be lethal [22, 26, 27] . Richenel et al. [22] described 64 patients given remission induction courses of intermediate dose cytarabine to treat AML, ALL and highgrade NHL. Seven (11%) of sixty-six induction courses and eight (21%) of thirty-eight consolidation courses were complicated by respiratory failure considered to be a complication of the cytarabine. The radiological abnormalities ranged from diffuse interstitial, mixed interstitial alveolar, or alveolar pulmonary changes.
Dyspnoea has also been reported in patients treated with gemcitabine and is said to occur in 8% of patients. In 5% this is described as severe [13] . Three patterns of dyspnoea have been recorded; these are an acute hypersensitivity reaction with associated bronchospasm, nonspecific dyspnoea of uncertain aetiology occurring within days of treatment and settling spontaneously, and a rare idiosyncratic reaction associated with pulmonary infiltrates on chest X-ray [9, 13, 29] . Withdrawing treatment and adding corticosteroids has resulted in a rapid resolution of the symptoms and radiological changes in these latter cases [13] .
Pulmonary toxicity with gemcitabine has been described in a number of phase II trials. Carmichael et al. treated 40 patients with metastatic breast carcinoma [9] . The patients received 800 mg/m 2 of gemcitabine once a week for three weeks followed by a one week break. Of the 40 patients treated 5 developed shortness of breath. In one patient this occurred 30 minutes following the infusion and was associated with bronchospasm; the dyspnoea resolved with nebulised bronchodilators. In three other patients delayed mild and transient pulmonary symptoms occurred. In the fifth patient symptoms were more severe with pulmonary infiltrates evident on both CXR and CT scan. These infiltrates resolved when the drug was discontinued and corticosteroids commenced.
Yokoyoma et al. [4] treated 67 patients with non-smallcell lung cancer in a multi-centre phase II trial with gemcitabine 1000 mg/m 2 given weekly for three weeks followed by a one week break. One patient who was known to have a mild pre-existing pulmonary fibrotic condition experienced severe dyspnoea and fever after just one cycle of chemotherapy. Despite corticosteroids and oxygen therapy his pulmonary fibrosis progressed and the patient died of this seven months later.
Gatzemeier et al. [30] treated 50 patients with ad-vanced non-small-cell lung cancer in a phase II trial with a combination of gemcitabine and ifosfamide. Six of these patients developed radiological evidence of pneumonitis that resolved with corticosteroids. Gemcitabine has also been used with concomitant radiotherapy. This has shown good response rates but an unacceptably high incidence of pulmonary toxicity, for this reason its use with radical radiotherapy is no longer licensed in the UK.
Paclitaxel and docetaxel are members of the taxane family. These drugs are highly active against solid tumours including ovarian, breast and non-small-cell lung cancer.
Paclitaxel has clearly been associated with pulmonary toxicity. Khan et al. described bilateral pneumonitis in three patients with differing underlying malignancies treated with paclitaxel 200 mg/m 2 . Pulmonary infiltrates occurred just six hours following the three-hour infusion. The radiological signs resolved within 24-96 hours. The patients were subsequently treated prophylactically with diphenhydramine and hydrocortisone [17] . Ramesh et al. reported three patients who developed pulmonary infiltrates two days to two weeks following administration of paclitaxel. One patient received steroids but infiltrates resolved completely in all three patients [16] .
Unlike paclitaxel, dyspnoea with docetaxel has been less well documented. Recently, however, Merad et al. [14] highlighted two cases of interstitial pneumonitis during docetaxel chemotherapy given for non-small-cell lung cancer (NSCLC) at a dose of 100 mg/m 2 of docetaxel three-weekly as a three-hour infusion without premedication. These patients became dyspnoeic between cycles 2-4 at which time radiological evidence of pulmonary infiltrates could be seen on CXR. These infiltrates resolved when the drug was discontinued and corticosteroids commenced. The mechanisms behind the pulmonary injury were unclear; however, it is thought that both direct and indirect factors are involved. Direct damage is considered to occur because of reactive oxygen metabolites produced by the action of docetaxel. Indirectly docetaxel induced immunomodulation has been suggested causing the proliferation of cytotoxic T cells against a specific pulmonary antigen expressed by the tumour [14] .
The combination of docetaxel and gemcitabine has been evaluated in a number of tumour types in phase II studies, Georgoulias et al. [33] reported a response rate of 53% in chemotherapy naive patients treated with this combination for advanced non-small-cell lung cancer. This response rate was far higher than those obtained by either drug alone. The doses in this study were 900 mg/m 2 of gemcitabine on day 1 and 8 and 100 mg/m 2 of docetaxel on day 8. They concluded that the gemcitabine/docetaxel combination had significant anti-tumour activity and was well tolerated. They hypothesised that the two drugs had a synergistic anti-tumour activity because of the different cellular targets affected by the drugs and the different phases of the cell cycle at which they act. There were no cases of pulmonary toxicity described.
Both paclitaxel and docetaxel have been associated with fatal pulmonary toxicity when used concomitantly with radiotherapy [18, 19, 33] . With the increasing use of both gemcitabine and taxanes as single agents and in combination with one another and/or radiotherapy these complications must be carefully considered. In our study, we have described a high incidence of pulmonary toxicity with three out of five patients developing symptoms and radiological evidence of pulmonary infiltrates which proved fatal in one case. It is unclear whether this was a chance phenomenon, or whether there is an enhanced risk of pulmonary toxicity with this particular combination. It is, however, clear that as single agents both gemcitabine and docetaxel can cause significant pulmonary toxicity which may result in the development of progressive pulmonary infiltrates.
The clinical condition of our patient that died following lung biopsy particularly deteriorated following high dose oxygen therapy. It must be possible that this rapid deterioration with resulting adult respiratory distress syndrome could have been accelerated by high dose oxygen rather as seen with high dose oxygen in association with bleomycin.
This combination of chemotherapy was easy to administer in an outpatient setting and was generally well tolerated with promising responses seen. Patients treated with this combination should be carefully monitored with CXR, pulmonary function tests and chest CT scanning where necessary. If any of these tests show evidence of pulmonary infiltrates or if the patient complains of dyspnoea we would recommend discontinuation of the treatment. Other causes of pulmonary infiltrates e.g., lymphangitis carcinomatosis, infection, cardiogenic oedema, pulmonary haemorrhage and allergy should be excluded. Following appropriate investigations corticosteroids should be commenced and continued until symptoms and pulmonary infiltrates improved. It may be prudent to exclude patients with significant preexisting pulmonary complaints from this treatment. We would encourage caution when treating patients who have previously received chest irradiation and would recommend care with high dose oxygen when pulmonary complications with infiltrates develop.
Note added in proof
A further two patients have received chemotherapy in the DGC trial. One of these had developed evidence of pulmonary toxicity. After five cycles of docetaxel 60 mg/m 2 and gemcitabine 800 mg/m 2 (days 1 and 14) he became increasingly dyspnoeic with evidence of pulmonary infiltrates seen on CT scan. The combination of drugs has been discontinued and the patient is improving following the commencement of corticosteroids.
